Better testing for Pneumocystis in people with weakened immune systems
Official title: Optimisation du Diagnostic de Pneumocystose Chez Les Patients Immunodéprimés
Run by Assistance Publique - Hôpitaux de Paris · NCT06890078 · Data updated 2026-11-12
This project will try a new qPCR test on non-invasive respiratory samples to see if it can detect Pneumocystis in immunocompromised adults compared with standard reference tests.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 240 (estimated) |
| Sponsor | Assistance Publique - Hôpitaux de Paris Academic / other |
| Locations | 4 sites (Paris and 3 other locations) |
| Status | Recruiting |
| Started | July 8, 2025 |
| Main results expected | July 8, 2027 |
| Study ends | July 8, 2027 |
| Registry record updated | April 23, 2026 |
| Trial ID | NCT06890078 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults who are immunocompromised with suspected Pneumocystis pneumonia who are scheduled for bronchoscopy with BAL or for induced sputum, who have not received more than 72 hours of Pneumocystis treatment and can give non-opposition/consent.
✕Probably not a fit
Patients already treated for more than 72 hours, children, pregnant or breastfeeding people, and those unable to give consent or deprived of liberty are unlikely to benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational protocol will collect biological samples (induced sputum and bronchoalveolar lavage when clinically indicated) from immunocompromised adults with suspected Pneumocystis pneumonia. qPCR will be performed on non-invasive samples and results compared to reference techniques from BAL or induced sputum. Key exclusions include more than 72 hours of prior Pneumocystis treatment, pregnancy or breastfeeding, and persons deprived of liberty or unable to give non-opposition/consent. The goal is to determine whether non-invasive qPCR can reliably provide a positive diagnosis and reduce the need for invasive bronchoscopic sampling.
Why it matters
Potential benefit: If successful, this approach could allow accurate diagnosis from less invasive samples, reducing bronchoscopy procedures and speeding appropriate treatment.
How similar studies have gone: Prior work has shown qPCR can detect Pneumocystis in respiratory samples with good sensitivity, but findings vary by sample type and clinical setting so non-invasive approaches remain under active validation.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * adult patients with suspected pneumocystis * with an indication for bronchial fibroscopy for BAL or induced sputum * no opposition to the research from the adult patient or his or her next of kin research for patients unable to express their non-opposition Exclusion Criteria: * Pneumocystis treated for more than 72 hours * pregnancy/breast-feeding * adult patients deprived of liberty, protected
Where it's running
-
Hôpital Lariboisière AP-HP Maladies infectieuses
Paris, France Recruiting -
Hôpital Saint Louis AP-HP Maladies infectieuses
Paris, France Recruiting -
Hôpital Saint Louis AP-HP Réanimation
Paris, France Recruiting -
Hôpital Saint-Louis AP-HP Pneumologie
Paris, France Recruiting
Study contacts
- Study coordinator: Agathe Vigouroux, MD
- Email: agathelaure.vigouroux@aphp.fr
- Phone: 0142494683
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Oral switch for bloodstream infections in immunocompromised children
This trial tests whether switching from IV to oral antibiotics is just as safe as continuing IV therapy for children with bloodstream infections who are immunocompromised or have a central venous catheter.
-
Biomarkers of Inflammation, Infection, and Immunity in Critically Ill Patients
This study tests whether blood biomarkers can predict illness severity and complications in adults admitted to intensive care with infection, including sepsis, and in immunocompromised or high-risk surgical patients.
-
FUNGAL-P: A score to spot fungal pneumonia early in adults with pneumonia
Aimed at adults with pneumonia, this study tests a new score to help identify fungal pneumonia sooner so doctors can test appropriately and start antifungal treatment when needed.
-
Personalized immunological score to predict severe infections in transplant and immunocompromised patients
This project will test whether a personalized immunological score can predict serious infections in transplant and other immunocompromised patients and help tailor their care.
-
Recombinant shingles vaccine for frail and immunocompromised adults
This project will test whether a recombinant shingles (herpes zoster) vaccine produces protective immune responses and is safe in frail adults with weakened immune systems.
-
Nasal immune responses to respiratory viruses in immunocompromised and healthy adults
See how nasal immune responses to respiratory viruses differ between immunocompromised adults and healthy adults.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.